Boomerang Ventures

Navigare Ventures is an early-stage investor specialized in science-driven companies. Through our investments, we strengthen the industrial and societal impact of research, as well as the long-term financial capacity of our owners, Wallenberg Investments AB. Our core investment themes within deep tech are underpinned by our knowledge and network in a number of scientific fields and industries. These include advanced computing and quantum technologies, synthetic biology and bio innovation, advanced materials and nano technology as well as data-driven life science. We are long term investors - Seed and Series A and beyond - and form deep and lasting partnerships with founders and entrepreneurs. Our extensive industrial and scientific networks gives us the opportunity to provide capital, network, and know-how to transform promising science start-ups into successful companies. Who we are Navigare Ventures, based in Stockholm, is a fully owned subsidiary of Wallenberg Investments AB. We are a team of scientists, industrialists and entrepreneurs who understand the challenges of turning cutting-edge technologies to successful ventures. As part of the Wallenberg ecosystem, our returns fuel the next generation of scientific advancement through research funding from the Wallenberg Foundations to Swedish universities. What we are looking for We partner with experienced entrepreneurial teams that combine scientific excellence with strong business acumen. In this respect, your company should have a unique offering based on a profound understanding of your scientific or technological field and its market and industrial environment. You should also be capable of demonstrating the viability and commercial potential of your product by engaging with real customers. You are raising capital to scale the R&D, production, marketing, and sales capabilities of your company. Our investment philosophy We only invest in companies we understand. While this is an important general principle in any investment activity, it is even more important when making early-stage investments in new technology. If we don’t understand your science, we won’t understand what experts tell us about the value chain and how it works, or what the competitive landscape looks like. And most importantly, we won’t be able to help you develop your strategy and navigate through the challenges of deep-tech start-ups. So, when preparing a meeting with us, don’t put too much emphasis on future revenue projections. That’s important too, in due time. But first, be prepared for long sessions in front of a whiteboard, explaining to us how your material, algorithm, or antibody functions. We don’t need to understand all the equations, but we need to get the heuristics. We are scientists at heart, eager to learn, and we carry a deep conviction that the world is fundamentally understandable. Core investment themesAdvanced computing and quantum technologies: Digitization and automation deepens in industry and society, driven by breakthroughs in computing and AI. Our focus includes improving existing technologies as well as finding completely new platforms in AI and other areas of applied mathematics as well as in novel computer architectures, communication technology, hardware and design. Synthetic biology and bio innovation: Synthetic biology and bio innovations contribute to a more sustainable society. Companies in this field often combine principles of biology, engineering, and computer science for the development of new biological products and manufacturing methods. Advanced materials and nano technology: New materials and nanoscale technology enable disruptions with the potential to benefit numerous existing industries. From quantum materials to biomaterials and biologically inspired nanostructures, we look for the most promising technology platforms in the field. Data-driven life science: Combining digital technology and data with life science drives scientific understanding and enables novel products. Our focus is on data-driven methods to increase personalization and precision of medical interventions, accelerate product development, digitalize care among other advancements.

At Menlo Ventures, we go ALL IN. This isn’t just a motto, but how we show up everyday for the companies we back, the investors who back us, and each other. When we win, we win as a team. 47 Years 80+ Public Companies 165 + Mergers + Aquisitions $5B+ Under Management We focus on the "three stages of early" We are investors and company builders - we know what it takes to turn a budding idea into a scalable business. We work with early-stage founders to find product-market fit, develop go-to-market strategies, scale their organizations, and support them as they grow. Inception: Our Menlo Labs team helps founders validate early-stage ideas, de-risk opportunities, and build successful foundations. Venture: Our venture team provides series A and B startups with guidance and hands-on help as they build their teams and products. Inflection: Our inflection team supports early growth-stage startups during critical points as they prepare to scale. Our focus areas At every stage from inception through IPO, we invest in game-changing ideas that reinvent life and work. Although we remain open to new ventures within consumer, enterprise, and healthcare, we go deep in the following seven focus areas: AI: Generative AI is breaking into every software vertical, and winners in these markets will create massive economic and societal value. Menlo Ventures is placing bets on the most promising GenAI companies at the infrastructure and application layers, where we see immense potential for groundbreaking businesses that will reshape industries and push the boundaries of what we can achieve. Bio + Healthcare: Innovations at the intersection of advancements in technology and biology will drive major improvements in the quality of our health and the cost of healthcare. At Menlo, we invest at that intersection - backing breakthrough digital health companies (vertical SaaS and digital care) and novel life sciences companies (therapeutic platforms and transformative technologies). Consumer: The world we live in today is enhanced by technologies we might not have thought possible even 10 years ago. There is so much still to come. At Menlo, we invest in the game-changing companies of the future, those that will help us do things better, faster, or cheaper than we can today. Cloud Infrastructure: As enterprises continue migrating to the public cloud, a new generation of companies will write the playbook for the underlying infrastructure that powers their applications. These tools and platforms are built for and cater to the developer, optimized for time-to-integration with beautiful, easy-to-use UIs and APIs. Cybersecurity: In a complex, post-pandemic world, rapid cloud adoption and the proliferation of open-source software have dramatically expanded the attack surface for bad actors against enterprises, governments, and their applications. Additionally, the shift-left approach to software development requires developers to embrace a security-first mindset. As the cyber war continues, Menlo will back the best teams fighting on the frontlines. Fintech: Financial transactions and services power the global economy. Menlo invests in four fintech categories: dev-focused infrastructure and embedded finance (API layers), vertical banking, end-to-end financial services for consumers and SMBs, and tools that serve finance teams and the office of the CFO. SaaS: The shift to the cloud introduced an entirely new business model–Software-as-a-Service–and created unprecedented opportunities for enterprise software companies. Menlo divides the SaaS landscape into three categories, each with a distinct point of view that guides our investment, research, and resources: Departmental SaaS, Vertical SaaS, and Horizontal SaaS. Supply Chain + Automation: This once-in-a-generation reinvention/reinvigoration of the supply chain will create a world that is more efficient, resilient, and sustainable because of the operational efficiencies we gain. With an eye on a more functional future, Menlo invests in a broad range of technologies–robotics and industrial automation among them.

Digitalis Ventures engineers solutions to unmet needs in health. Our deep technical, financial, and domain expertise enables us to drive solutions across venture investing, technology development, and public-interest problem-solving. DV INVESTMENTS DV Investments provides venture capital to early-stage companies across life sciences, health technology & services, and animal health with the goal of supporting our portfolio companies throughout their development. DV PROVING GROUNDS DV Proving Grounds designs, develops, and delivers entrepreneurially-driven solutions to unmet needs in health through data science, technology development, and new ventures. DIGITALIS COMMONS Digitalis Commons is a non-profit organization affiliated with Digitalis Ventures. The Commons builds frontier-advancing, scalable solutions that have an outsized impact on important problems in health and health care.

We build and invest in companies that positively impact human health with smart solutions, breakthrough science and technology. Our focus is on innovation in digital healthcare, connected medical devices, and life sciences We focus on therapeutic and preventive technology solutions addressing unmet needs in some of the most vulnerable segments of society: women, children and the elderly. Digital transformation will continue to shape our lives and has the potential to transform care. We aim to build and support Digital Health & Life Sciences companies working to make healthcare smarter, using data to improve care and outcomes, and reinventing the patient journey. Our vision for the future of healthcare guides our investment strategy. A data driven digital transformation will shape the future of healthcare. The traditional biopharma model will evolve into an integrated model, where prevention, precision cure, and care management will coexist in a highly personalized patient-centric solution. Our goal is to support the creation of life transforming care products and therapies. We believe the future of healthcare lies in supporting the next-generation of founders and teams who will lead us there. What do we look for?Innovation and groundbreaking opportunities in our sectors of focus: digital health, life sciences, tech-enabled care delivery, and connected devices Innovative treatments for Central Nervous System (CNS) disorders, in particular neurodevelopmental disorders, mental health and epilepsy Founders and teams with domain expertise who seek collaborative investment partners Investments that span development and commercial phases, with a focus on early stage opportunities (Pre-Seed to Series A). Our investment approachOur investment approach combines direct investments in early-stage companies with venture creation from bold ideas in global innovation hubs Our goal is to enable talented entrepreneurs to scale more quickly and effectively through access to our capital, enterprise capabilities and consumer touchpoints, while offering expertise and insights from Angelini’s unique perspective. We invest primarily across Europe, North America and Israel, recognizing that healthcare technology innovation is occurring in many cities around the world. We have committed €300M for investments and company creation in digital health and life sciences. What do we commit to you?Active and involved healthcare investors who operate with integrity, approachability, and transparency A team of passionate healthcare and venture capital experts diverse in demographic and experience A track record of success and experience navigating the ups and downs of early-stage company building Access to a world-class advisory board to leverage C-level experience, expertise, and leadership in healthcare

Founded over 20 years ago, Kaiser Permanente Ventures has developed into a national leader in strategic venture investing in healthcare. In partnership with Kaiser Permanente and our limited partners, the KPV team has invested in and helped support over 65 companies, representing some of the most important innovations in healthcare delivery over this time period. We’ve achieved these successes through deep engagement within KP and across our investment partners, leveraging the tremendous insights that come from those leading our healthcare systems and care delivery to identify the most pressing needs within healthcare and select the innovations that most effectively address those opportunities. Together with our partners, KP and KPV represents22,000+ clinicians and over 180,000 healthcare employees 38+ acute care hospitals and over 600 other healthcare-related facilities Approximately $65 billion in annual operating revenue Largest U.S. single comprehensive electronic medical record system Leading evidence-based care delivery mode Our fund targetsHealth Information Technology (Enterprise Solutions) Digital Health Healthcare Services Medical Devices Diagnostics and Precision Medicine

We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach As the corporate venture capital arm of Sanofi, we invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. We invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value through future financings and IPO. How We Work Think of us like institutional venture capitalists with an added bonus: in addition to our investment, we aim to offer our portfolio companies select access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. Our goal is to foster strong relationships over time so when our portfolio company is ready to consider a partnership or acquisition, our colleagues on the BD and M&A teams can be a first and last call. We move quickly, we don’t believe in drawn-out processes, and we always aim to provide thoughtful feedback. Our Investment Focus We invest in early-stage biotech and digital health companies of strategic interest to Sanofi. We seek to accelerate all strategic focus while reaching into novel and emerging areas of science and technology. Here are some of the areas that we currently are thinking about: Rare diseases Immunology and inflammation Oncology Cell and gene therapy Vaccines Digital health and data science We can't do it alone - we would love to hear how we can team up to improve human health for people everywhere!